On 13 May 2026, the Food and Drug Department, Ministry of Health, Lao PDR issued certificates of drug registration for ALI-TIRZEP® (tirzepatide) in eight presentations, under registration numbers 04-LM-01461-26 through 04-LM-01468-26.
ALI-TIRZEP is manufactured by Alliance Pharmaceutical Co., Ltd at Simmanoneua Village, Hadsayfong District, Vientiane Capital, and is supplied to authorized distributors in Lao PDR.
ALI-TIRZEP is a prescription medicine. The indications, dosage, contraindications, warnings and adverse effects set out in the approved prescribing information are published in full on each product page below, and prescribing decisions should be based on that document.
Registered presentations
- ALI-TIRZEP 2.5mg Single-Dose — 2.5 mg / 0.5 mL — Reg. 04-LM-01465-26
- ALI-TIRZEP 5mg Single-Dose — 5 mg / 0.5 mL — Reg. 04-LM-01466-26
- ALI-TIRZEP 7.5mg Single-Dose — 7.5 mg / 0.5 mL — Reg. 04-LM-01467-26
- ALI-TIRZEP 10mg Single-Dose — 10 mg / 0.5 mL — Reg. 04-LM-01468-26
- ALI-TIRZEP 10mg Multi-Dose — 10 mg / 2.4 mL — Reg. 04-LM-01461-26
- ALI-TIRZEP 20mg Multi-Dose — 20 mg / 2.4 mL — Reg. 04-LM-01462-26
- ALI-TIRZEP 30mg Multi-Dose — 30 mg / 2.4 mL — Reg. 04-LM-01463-26
- ALI-TIRZEP 40mg Multi-Dose — 40 mg / 2.4 mL — Reg. 04-LM-01464-26
Verifying a genuine pen
Genuine ALI-TIRZEP® is supplied only as a cartridge pen and carries a unique encrypted anti-counterfeiting QR code on the side of the outer carton. Counterfeit products imitating ALI-TIRZEP® have been reported in circulation. To report a suspected side effect, a quality problem or a suspected counterfeit, please use the medicine safety form.
Official updates from Laos Alliance Pharmaceutical Group — investments, milestones and press releases.
